Events

Meet the iOnctura team at the following events:

iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair

Geneva, Switzerland, 27 May 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has appointed Dr. Joanna Horobin as non-executive Chair to the iOnctura Board with immediate effect.  Joanna Horobin M.B., Ch.B. is an accomplished drug developer and biotech leader with … Continue reading “iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair”

A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry

Click here to see the PDF abstract from AACR Click here for abstractsonline.com A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry A MacQueen, G Viticchie, I Powley, F Finotello, K Niewola, P Shah, L van der Veen, M Lahn & … Continue reading “A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry”

Characterisation of novel CD73 antibodies as a therapeutic method of adenosine regulation

Click here to see the PDF abstract from AACR Click here for abstractsonline.com Grainne Gernon, Suzanne Grooby, Louise Tonkin, Anja-Christina Bitterwolf, Lorna Stewart, Pritom Shah, Katherine Ewings, Zoë Johnson CD73 is a membrane-bound nucleotidase receptor which is frequentlyoverexpressed in the tumour microenvironment and can be found on both tumour and immune cell types. Its function is … Continue reading “Characterisation of novel CD73 antibodies as a therapeutic method of adenosine regulation”

iOnctura in the news: Emerging Company Profile by Scrip Informa Pharma Intelligence

iOnctura Develops Next-Generation PI3K-Delta Inhibitors For Cancer Executive Summary Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis. The European start-up iOnctura SA is developing candidate products with immuno-oncologic and direct anti-tumor properties, and has just dosed its first patient in a … Continue reading “iOnctura in the news: Emerging Company Profile by Scrip Informa Pharma Intelligence”

iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours

Geneva, Switzerland, 26 February 2020: iOnctura SA., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces it has  dosed the first patient in a first-in-human dose escalation and expansion study evaluating the safety and preliminary efficacy of its lead programme IOA-244, which is being developed as a … Continue reading “iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours”

iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects

iOnctura SA is delighted to announce today that it has exercised its exclusive global option to license two of Cancer Research UK’s projects, which are the result of a successful strategic alliance programme with CRUK-Therapeutic Discovery Labs (TDL). Under the terms of the licence agreements iOnctura will be solely responsible for the development and commercialisation … Continue reading “iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects”

iOnctura Expands its Clinical Advisory Board

Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the addition of new members to its Clinical Advisory Board (CAB) with the appointment of Dr. Hendrik-Tobias Arkenau, Executive Medical Director, Sarah Cannon Research Institute, UK, and Dr. Jordi Rodón Ahnert, … Continue reading “iOnctura Expands its Clinical Advisory Board”

iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development

Amsterdam, The Netherlands, January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a EUR 15 million Series A financing. The financing was led by INKEF Capital and co-led by VI Partners with participation by new investor Schroder Adveq. … Continue reading “iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development”

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH